New research reveals potential biomarkers for epilepsy diagnosis

New research led by UTHealth Houston scientists uncovered two genes associated with variants linked to epilepsy, which showed specific traits that make them promising diagnostic biomarkers.

High Tide Q2 Revenue Flat to Q1 at C$118.1 Million

High Tide Reports Third Consecutive Quarter of Record Revenue and Adjusted EBITDA of $118.1 Million and $6.6 Million, Respectively The Company Achieved Significant Sequential Improvement

June 15, 2023

Confirmed Antitumor Activity with T-DXd for HER2-Positive Metastatic CRC

The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC). Almost 40% of patients treated

August 17, 2024

Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.